Lifeward (NASDAQ:LFWD) Issues Earnings Results, Misses Estimates By $0.66 EPS

Lifeward (NASDAQ:LFWD) announced its quarterly earnings data on Friday. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.66), FiscalAI reports. The firm had revenue of $5.43 million during the quarter, compared to analysts’ expectations of $7.24 million. Lifeward had a negative return on equity of 235.86% and a negative net margin of 141.28%.

Lifeward Stock Performance

Shares of LFWD traded down $1.66 during mid-day trading on Friday, hitting $4.06. 30,374 shares of the company traded hands, compared to its average volume of 14,890. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.77 and a current ratio of 2.33. The stock has a 50-day moving average price of $6.42 and a two-hundred day moving average price of $6.87. Lifeward has a 1 year low of $3.81 and a 1 year high of $9.61. The stock has a market cap of $11.49 million, a price-to-earnings ratio of -0.24 and a beta of 0.55.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings raised Lifeward from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Lifeward in a research note on Friday, August 21st. Zacks Research raised Lifeward from a “strong sell” rating to a “hold” rating in a report on Monday, July 27th. Finally, Citigroup reaffirmed a “buy” rating on shares of Lifeward in a report on Friday, August 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Lifeward Company Profile

Lifeward Ltd. (NASDAQ: LFWD) is a medical technology company focused on developing and commercializing wearable robotic systems designed to help people with mobility impairments stand, walk and participate in rehabilitation. The company was formerly known as ReWalk Robotics and adopted the Lifeward name in 2024. Lifeward’s principal product line is the ReWalk Personal Exoskeleton, a battery-powered wearable robotic device intended to enable individuals with lower-limb disabilities, including those resulting from spinal cord injury, to walk with the assistance of crutches or other support.